Asia Pacific Vascular Graft Market size crossed USD 555.8 million in 2020 and is projected to expand at over 7.1% CAGR from 2021 to 2027.
Vascular graft is an important method to surgically treat diseased or damaged blood vessels in order to restore blood flow by replacing the blood vessels. Replacing healthy blood vessels timely would ensure increased life expectancy and this provides more control over patient health.
Get more details on this report - Request Free Sample PDF
Increasing prevalence of chronic kidney disease in Asia Pacific region such as India, China and Japan among others will drive the regional vascular graft market growth. For instance, according to Asia Pacific Society of Nephrology report, about 17% of Indians suffer from chronic kidney disease. Also, the report stated that, nearly 40% of diabetes patients develop symptoms of end-stage renal disorders in India. Thus, growing prevalence of diabetes coupled with high number of chronic kidney diseases will lead to increasing incidence of end-stage renal disorders, thereby compelling the need for hemodialysis.
Furthermore, rising pervasiveness of thoracic & abdominal aortic aneurysms and peripheral aortic disease among growing geriatric population will favor the market expansion. However, infection associated with vascular graft and lack of skilled professionals in developing countries may restrain the market growth.
Asia Pacific Market, By Application
The abdominal aortic aneurysm repair segment accounted for USD 180 million revenue in 2020. Abdominal aortic aneurysm (AAA) is a serious healthcare condition associated with swelling of aorta leading to serious health complications. It is most common among adults aged 60 years and above. Thus, increasing geriatric population along with favorable reimbursement policies will favor segment growth. Furthermore, with introduction of minimally invasive surgeries leading to shorter hospital stay and quick recovery, the demand for abdominal aortic aneurysms repair will escalate in the future.
Asia Pacific Market, By End-use
Hospital segment dominated around 62.6% Asia Pacific vascular graft market share in 2020 due to the increasing number of healthcare policies and favorable reimbursement scenarios, as it will lead to increasing number of admissions in the hospitals. In addition, advanced surgical procedures offered in hospitals along with growing burden of cardiovascular and renal disorders will propel the segment growth. Furthermore, growing patient pool coupled with introduction of innovative surgical procedures will render positive impact on the market revenue.
Asia Pacific Market, By Raw Material
Polyester vascular grafts market will show significant growth of 7.5% through 2027. High growth is attributed to its high success rate and stable biological seal coupled with various technological advancements. Also, the growth of polyester graft segment is driven by high demand for polyester material-based grafts. Further, the polyester material grafts provide better blood compatibility, high durability, tensile strength that will contribute to the demand of this segment.
Asia Pacific Market, By Country
China vascular graft market size is set to register 7.2% growth rate during the forecast timeframe impelled by the improving healthcare infrastructure and increasing incidences of CVDs and diabetes in the country. Moreover, rapid epidemiological transition has resulted in high number of premature deaths is expected to boost the demand for minimally invasive grafting procedures. Moreover, with introduction of innovative and novel vascular bypass procedures, the demand for vascular grafts has escalated in the country.
Competitive Industry Landscape
Prominent companies operating in Asia Pacific vascular graft market include Becton Dickinson (C.R. Bard), B. Braun Melsungen, Cook Medical, Endologix, Getinge AB, LeMaitre Vascular, Medtronic, among others.
Companies undertake various strategies such as mergers, collaborations, acquisitions, and geographic expansions to strengthen their market share. For instance, in October 2019, Medtronic announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and launched Valiant Navion Thoracic Stent Graft System in Japan. The system is used in minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). This strategy enabled company to expand its product offerings in untapped economies, thereby strengthening its market presence.